MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.17
+0.18
+1.29%
After Hours: 14.18 +0.01 +0.06% 16:16 07/02 EDT
OPEN
14.23
PREV CLOSE
13.99
HIGH
14.39
LOW
13.75
VOLUME
419.93K
TURNOVER
--
52 WEEK HIGH
29.97
52 WEEK LOW
10.32
MARKET CAP
657.33M
P/E (TTM)
-5.1164
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RDUS stock price target is 25.86 with a high estimate of 39.00 and a low estimate of 17.00.

EPS

RDUS News

More
Do Hedge Funds Love Radius Health Inc (RDUS)?
Insider Monkey · 06/16 15:44
Edited Transcript of RDUS earnings conference call or presentation 7-May-20 8:45pm GMT
Q1 2020 Radius Health Inc Earnings Call
Thomson Reuters StreetEvents · 06/10 18:33
Why Is Radius Health (RDUS) Down 11.6% Since Last Earnings Report?
Zacks · 06/06 16:31
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
GlobeNewswire · 05/27 10:00
Benzinga's Top Upgrades, Downgrades For May 13, 2020
Upgrades
Benzinga · 05/13 13:58
Morgan Stanley Downgrades Radius Health to Equal-Weight, Announces $20 Price Target
Morgan Stanley analyst Vikram Purohit downgrades Radius Health (NASDAQ:RDUS) from Overweight to Equal-Weight and announces $20 price target.
Benzinga · 05/13 10:20
JP Morgan Maintains Overweight on Radius Health, Lowers Price Target to $27
JP Morgan maintains Radius Health (NASDAQ:RDUS) with a Overweight and lowers the price target from $32 to $27.
Benzinga · 05/12 15:09
Radius Health, Inc. (RDUS) CEO Kelly Martin on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/09 06:34

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About RDUS

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
More

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.